Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019

Nebulized ensifentrine as add-on to dual bronchodilator therapy for COPD demonstrated additional increase in lung function on top of maximum current therapy in three-day Phase 2 clinical trial Single...
May 02, 2019 07:00 ET | Source: Verona Pharma plc

Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference

LONDON, May 02, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it...
May 01, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker

LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to...
May 01, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update

LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it...
April 25, 2019 07:07 ET | Source: Verona Pharma plc

Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019

LONDON, April 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...
April 09, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine

LONDON, April 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to...
April 04, 2019 02:00 ET | Source: Verona Pharma plc

Grant of Options and RSUs and PDMR Dealings

LONDON, April 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
March 26, 2019 03:00 ET | Source: Verona Pharma plc

Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference

LONDON, March 26, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing...
March 25, 2019 03:00 ET | Source: Verona Pharma plc

PDMR Dealing

LONDON, March 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
March 22, 2019 12:00 ET | Source: Verona Pharma plc

2018 Annual Report and Accounts and Notice of AGM

LONDON, March 22, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing...